Genetic Polymorphisms Of XPA,XPC And XRCC1 Are Correlated With The Prognosis Of Non-small-cell Lung Cancer Patients Treated With Platinum-based Chemotherapy

Objective: To analyaze the correlations between genetic polymorphisms of XPA -4G/A,XPC Lys939Gln, XRCC1 Arg399Gln and the survival of non-small-cell lung cancerpatientswhoreceivedplatinum-basedchemotherapy.Methods: DNA was extracted from peripheral venous blood of 262 non-small-cell lungcancer patients before chemotherapy. The patients were routinely treated withplatinum-based chemotherapy. Taqman Real-time PCR was used to type the SNP of XPA,XPC and XRCC1. The relationship between genotypes and median survival time (MST)wasexplored.Results: Both the genetic polymorphisms of XPA -4G/Aand XRCC1 Arg399Gln were notseen significant correlation with the survival of non-small-cell lung cancer patients treatedwith platinum-based chemotherapy(P>0.05). The median survival time of the patients withXPC Lys939Gln Homozygous mutant genotype Gln/Gln (10.7 months)was significantshorter than the patients with genotype Lys(Lys/Lys or Lys/Gln,MST=19.1 months)(P=0.02), Cox ratio hazard models showed that the patients with mutant genotype Gln/Glnhad significant higher the risk of death than the patients with genotype Lys(Lys/Lys or Lys/Gln) (HR,1.78;95%CI,1.07-3.17; P=0.026).Whenwecomparedcombinationsofvariant alleles across both the polymorphisms of XPA and XPC, we didn't find that agreaternumberofvariantalleleswereassociatedwiththedeathriskofpatients.Conclusions: It suggested that XPC Lys939Gln might bea prognostic marker of survivalfor non-small-cell lung cancer patients receiving platinum-base chemotherapy. The twopolymorphisms of XPA and XPC might not have synergic effect on the prognosis ofplatinumagents.Furtherverificationofthisresultisstillrequired,though.